Cargando…

Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer

PURPOSE: Quinoline-based ligands targeting cancer-associated fibroblasts have emerged as promising radiopharmaceuticals in different tumor entities. The aim of this retrospective study was to explore the potential of FAPI-PET/CT in the initial staging of esophageal cancer patients and its usefulness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ristau, J., Giesel, F. L., Haefner, M. F., Staudinger, F., Lindner, T., Merkel, A., Schlittenhardt, J., Kratochwil, C., Choyke, P. L., Herfarth, K., Debus, J., Haberkorn, U., Koerber, S. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Brief Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666016/ https://www.ncbi.nlm.nih.gov/pubmed/33063132 http://dx.doi.org/10.1007/s11307-020-01548-y

Ejemplares similares

Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers
por: Syed, M., et al.
Publicado: (2020)

Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT
por: Koerber, Stefan A., et al.
Publicado: (2021)

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT
por: Dendl, Katharina, et al.
Publicado: (2021)

Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
por: Koerber, Stefan A., et al.
Publicado: (2023)

Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

(68)Ga-FAPI-PET/CT in patients with various gynecological malignancies
por: Dendl, Katharina, et al.
Publicado: (2021)

Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer
por: Liermann, Jakob, et al.
Publicado: (2021)

Distinguishing Benign and Malignant Findings on [(68) Ga]-FAPI PET/CT Based on Quantitative SUV Measurements
por: Dabir, M., et al.
Publicado: (2022)

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?
por: Dendl, Katharina, et al.
Publicado: (2021)

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74
por: Glatting, Frederik M., et al.
Publicado: (2022)

Head-to-head Intra-individual Comparison of [(68)Ga]-FAPI and [(18)F]-FDG PET/CT in Patients with Bladder Cancer
por: Novruzov, E., et al.
Publicado: (2022)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Detecting and Locating the Site of Local Relapse Using (18)F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients—Potential Impact on PSMA-Guided Radiation Therapy
por: Koerber, S. A., et al.
Publicado: (2022)

Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial
por: Koerber, Stefan A., et al.
Publicado: (2019)

Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model
por: Liu, Yuwei, et al.
Publicado: (2021)

(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
por: Giesel, Frederik L., et al.
Publicado: (2019)

(68)Ga- or (18)F-FAPI PET/CT—what it can and cannot
por: Mori, Yuriko, et al.
Publicado: (2023)

FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies
por: Dendl, K., et al.
Publicado: (2021)

FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

Targeting of activated fibroblasts for imaging and therapy
por: Lindner, Thomas, et al.
Publicado: (2019)

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
por: Koerber, Stefan A., et al.
Publicado: (2021)

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review
por: Windisch, Paul, et al.
Publicado: (2020)

Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity
por: Ristau, J., et al.
Publicado: (2021)

A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
por: Loktev, Anastasia, et al.
Publicado: (2018)

Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
por: Loktev, Anastasia, et al.
Publicado: (2019)

[(68) Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease
por: Conen, Patrick, et al.
Publicado: (2022)

High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics
por: Kesch, Claudia, et al.
Publicado: (2021)

(18)F-labeled tracers targeting fibroblast activation protein
por: Lindner, Thomas, et al.
Publicado: (2021)

Activated fibroblasts in muscle sarcoidosis revealed by [(18)F]FAPI-74 PET
por: Watabe, Tadashi, et al.
Publicado: (2023)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021)

One-pot and one-step automated radio-synthesis of [(18)F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment
por: Naka, Sadahiro, et al.
Publicado: (2021)

Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
por: Hoppner, Jorge, et al.
Publicado: (2023)

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[(68)Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
por: Giesel, Frederik L., et al.
Publicado: (2015)

Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET
por: Gilardi, Laura, et al.
Publicado: (2022)

Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer
por: Giesel, F. L., et al.
Publicado: (2016)

Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review
por: Windisch, Paul, et al.
Publicado: (2021)

Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Intrafractional dose variation and beam configuration in carbon ion radiotherapy for esophageal cancer
por: Haefner, M. F., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l1u2vlm28vkj4q1433pn82h7gt